Compass Pathways: De-Risked (Still Risky) Psychedelics Play Enters Phase 3 (NASDAQ:CMPS)
Compass shares lost 82% of their value over the past 12 months. Read what this may mean for a company bringing a form of therapy using psychedelic drug psilocybin to market. Read more here.
Source: seekingalpha.com